Entity

Time filter

Source Type

Singapore, Singapore

Wei Hou H.,Massachusetts Institute of Technology | Wei Hou H.,Singapore Alliance for Research and Technology Center | Gan H.Y.,Massachusetts Institute of Technology | Gan H.Y.,Singapore Institute of Manufacturing Technology | And 8 more authors.
Biomicrofluidics | Year: 2012

Sepsis is an adverse systemic inflammatory response caused by microbial infection in blood. This paper reports a simple microfluidic approach for intrinsic, non-specific removal of both microbes and inflammatory cellular components (platelets and leukocytes) from whole blood, inspired by the invivo phenomenon of leukocyte margination. As blood flows through a narrow microchannel (20 × 20 μm), deformable red blood cells (RBCs) migrate axially to the channel centre, resulting in margination of other cell types (bacteria, platelets, and leukocytes) towards the channel sides. By using a simple cascaded channel design, the blood samples undergo a 2-stage bacteria removal in a single pass through the device, thereby allowing higher bacterial removal efficiency. As an application for sepsis treatment, we demonstrated separation of Escherichia coli and Saccharomyces cerevisiae spiked into whole blood, achieving high removal efficiencies of ~80% and ~90%, respectively. Inflammatory cellular components were also depleted by >80% in the filtered blood samples which could help to modulate the host inflammatory response and potentially serve as a blood cleansing method for sepsis treatment. The developed technique offers significant advantages including high throughput (~1 ml/h per channel) and label-free separation which allows non-specific removal of any blood-borne pathogens (bacteria and fungi). The continuous processing and collection mode could potentially enable the return of filtered blood back to the patient directly, similar to a simple and complete dialysis circuit setup. Lastly, we designed and tested a larger filtration device consisting of 6 channels in parallel (~6 ml/h) and obtained similar filtration performances. Further multiplexing is possible by increasing channel parallelization or device stacking to achieve higher throughput comparable to convectional blood dialysis systems used in clinical settings. © 2012 American Institute of Physics.


Bhagat A.A.S.,Clearbridge Biomedics | Lim C.T.,National University of Singapore | Lim C.T.,Mechanobiology Institute
Recent Results in Cancer Research | Year: 2012

Presence of circulating tumor cells (CTCs) in blood is an important intermediate step in cancer metastasis, a mortal consequence of cancer. However, CTCs are extremely rare in blood with highly heterogeneous morphologies and molecular signatures, thus making their isolation technically very challenging. In the past decade, a flurry of new microfluidic-based technologies has emerged to address this compelling problem. This chapter highlights the current state of the art in microfluidic systems developed for CTCs separation and isolation. The techniques presented are broadly classified as physical- or affinity-based isolation depending on the separation principle. The performance of these techniques is evaluated based on accepted separation metrics including sensitivity, purity and processing/analysis time. Finally, further insights associated with realizing an integrated microfluidic CTC lab-on-chip system as an onco-diagnostic tool will be discussed. © 2012 Springer-Verlag Berlin Heidelberg.


Trademark
Clearbridge Biomedics | Date: 2012-08-07

Detection apparatus for medical use, namely, medical apparatus for detecting cancer, medical apparatus for the detection of circulating tumor cells from blood; blood testing apparatus, apparatus for blood analysis, blood pressure monitors for medical use; blood component separation apparatus for medical purposes, cytometers for medical diagnostic use, namely, for blood cell analysis; cell culture apparatus for medical use, namely, cell culture chambers for cell sampling; blood filtration and filtering apparatus; cell counting units for medical use in the nature of cell culture chambers; medical blood filters and blood analysis apparatus; implantable devices for medical use in measuring the composition of body fluids; meters in the nature of medical diagnostic instruments for measuring body fluids.


Trademark
Clearbridge Biomedics | Date: 2011-08-04

Instruments for scientific use in treatment of samples before analysis, namely, instruments for detecting and isolating intact circulating tumor cells and other rare cells from small quantities of blood, instruments for staining samples for identification, instruments for retrieving samples for molecular analysis, automated laboratory equipment for cutting samples; detecting apparatus for detecting containments and rare cells for scientific laboratory use; blood cell separation and analyzing apparatus, other than for medical use; cell counting units for laboratory use; cases adapted for cells, namely, cell culture plates and bio-chips used for cell cultures and examination, transportation case for cells; specimen collection containers for samples extracted from the body for laboratory use; computer programs for scientific data analysis; computer imaging systems comprising of scanners, digital video recorders and printers; computer programs for image processing; fluid sampling apparatus, namely, medical fluid injectors, fluid handling device used for disposable bioprocessing applications and parts and fittings therefor; automated analyses for body fluids, other than for medical use, namely, automatic fluid-composition control machines and instruments, clinical laboratory analyzers for measuring, testing and analyzing blood and other bodily fluids or cells; apparatus for measuring body fluids, namely, measuring couplings for measuring temperature, pressure, quantity and concentration of fluids in hydraulic or pneumatic systems, rheometers for measuring the viscosity and viscoelasticity of fluids. Medical devices for diagnosis of rare cells, medical devices for infusion of fluids and medicine and injection devices for administering drugs, medical cutting devices, medical device for detecting cancer, medical device for treating cancer; medical devices, namely, ultrasound imaging apparatus, scanners and needle guides, and parts and fittings therefor; medical devices for monitoring blood properties; medical devices for obtaining body fluid samples; medical devices, namely, sample preparation device for medical diagnostic uses; detection apparatus for medical use, namely, medical diagnostic apparatus for detecting cancer or rare cells, flow cytometers and flow-based analyzers providing cell and particle detection, for medical use; apparatus for blood tests, analysis and monitoring for medical use, namely, blood testing apparatus, namely, blood collecting tubes, blood testing apparatus, namely, blood sampling tubes, blood component separation apparatus for medical purposes, apparatus for blood analysis, filters for blood and blood components, medical devices for monitoring blood properties; blood cell separation and analyzing apparatus for medical use; apparatus for medical cell sampling, namely, cell culture chambers for cell sampling; medical apparatus, namely, tubing and syringes assembly set and electromechanical fluidic instrument, and other similar or related devices, which enable blood cells sampling; blood filtration and filtering apparatus; cell counting units for medical use, namely, cell culture chambers, flow cytometers and flow-based analyzers providing cell counting for medical use, single-cell analyses; cell culture apparatus for medical use, namely, cell culture chambers, cell plates and wells; filtering apparatus and automated analyzers for body fluids for medical use, namely, medical filters for blood and blood components, automated medical diagnostic instruments for the analysis of body fluids; implantable devices for medical use in measuring the composition of body fluids; meters for body fluids, namely, medical diagnostic instruments for measuring body fluids; medical infusion pumps; blood extraction devices; test and screening devices for medical purposes, namely, cancer diagnostics, cardiovascular diagnostics, fetal cell diagnostics, infectious disease diagnostics, and for screening thereof; medical diagnostic testing apparatus for cancer detection; diagnostic imaging apparatus for medical use; apparatus for analyzing images for medical use, namely, medical image processors, cell counting and staining devices; specimen collection devices for medical use in extracting samples from the body.


News Article | September 21, 2015
Site: www.techinasia.com

A third installment of Singapore’s state-run Early Stage Venture Fund (ESVF-III) was announced today during TechVenture 2015, a conference organized by the country’s National Research Foundation (NRF). This latest tranche of the fund targeting the venture capital market will pour S$40 million (US$28.4 million) into establishing corporate venture funds by large local enterprises (LLEs). Dr. Vivian Balakrishnan, Singapore’s Minister for the Environment and Water Resources and Minister-in-charge of the country’s Smart Nation initiative, made the announcement during the event’s opening speech this morning. The idea is to help small, high-tech companies in Singapore grow through co-investments by the Singapore government and local private-sector players. According to the NRF, this allows for a technology ecosystem of small companies to grow around the larger ones that are putting in the money. This allows corporations to benefit from the technological innovations these smaller startups specialize in, while startups can tap into the resources and networks that larger firms have at their disposal. The ESVF was established in 2008 by the NRF in order to encourage researchers to commercialize their research ideas and help entrepreneurs establish and grow technology-based companies. The fund brings in venture capital firms to help grow the ecosystem by matching VC investments in early-stage tech startups on a 1:1 basis. Before this third installment, the fund had invested a total of S$100 million (US$71 million) into Singapore-based startups. During the first installment, it matched funds with VC firms Bioveda Capital, Extream Ventures, New Asia Investments, Raffles Venture Partners, and Walden International. For the second installment, it teamed up with Jungle Ventures, Golden Gate Ventures, SBI Ven Capital, Walden International, and Monk’s Hill Ventures. Notable startups that were funded by the ESVF and have successfully exited include YFind, HungryGoWhere, Brandtology, and JustCommodity, while others, such as Clearbridge Biomedics and Aslan Pharmaceuticals, received significant B-round investments. Other notable announcements during the first day of TechVenture include the SG-UK Joint Test-Bedding Initiative, implemented under the UK-Singapore Innovation and Research Partnership Agreement signed in October 2014. Under the agreement, small- and medium-sized enterprises from the UK and Singapore can pursue and establish partnerships with each other’s companies, universities, and organizations, in order to develop technologies for sustainable urban development. Finally, the NRF announced the establishment of the Lux Photonics Consortium, an alliance to develop collaboration between different institutes of higher learning in Singapore and private-sector players, to double down on photonics research. This particular area of research includes development of infrastructure for breakneck internet speeds by using new fiber-optic cables or electronic circuits powered by light. The NRF has invested around S$75 million (US$53.3 million) in grants for photonics research to Singapore’s Nanyang Technological University, National University of Singapore, and research and technology giant A*STAR. The institutes have partnered with the NRF and seven private-sector companies in establishing the consortium.

Discover hidden collaborations